The lost revenue from impending patent cliff’s i
Post# of 148181
“Depending on the company, on paper, the losses represent from 14% to 79% of their revenues,” Maria Whitman, global head of ZS Associates’ pharmaceutical and biotech practice, told BioSpace. “That’s $6 to $38 billion that any one company will lose in revenues. Another way to think about it is, five of today’s top 10 pharmas (by income) will have more than 50% of their revenues at risk.”
https://www.biospace.com/article/looming-pate...-of-truth/